These medications are not recommended for children and should be used for adults ≥18yrs old, unless otherwise specified.
|betamethasone dipropionate||Sernivo||0.05%||spray||Apply twice daily for up to max 4wks. Discontinue when control is achieved.|
|clobetasol propionate||Impoyz||0.025%||crm||Apply twice daily; max 50g/week and 2 consecutive weeks’ treatment per course. Discontinue when control is achieved.|
|Olux||0.05%||foam||Apply twice daily; max 50g/week or 21 capfuls/week and 2 consecutive weeks’ treatment per course. Discontinue when control is achieved.|
|halobetasol propionate||Bryhali||0.01%||lotion||Apply once daily for up to 8wks; max 50g/week. Discontinue when control is achieved.|
|Lexette||0.05%||foam||≥12yrs: apply twice daily for up to 2wks; max 50g/week. Discontinue when control is achieved. Treatment beyond 2 consecutive weeks: not recommended.|
|calcipotriene||Dovonex||0.005%||crm||Apply twice daily; gently rub in completely.|
|Sorilux||0.005%||foam||≥4yrs: apply twice daily; gently rub in completely. Apply to scalp when hair is dry.|
|calcipotriene + betamethasone dipropionate||Enstilar||0.005% + 0.064%||foam||≥12yrs: apply once daily for up to 4wks; max 60g every 4 days. Discontinue when control is achieved.|
|Taclonex||0.005% + 0.064%||oint, topical susp||Apply once daily for up to 4wks (oint) or 8wks (susp). 12–17yrs: max 60g/week. ≥18yrs: max 100g/week. Discontinue when control is achieved. Oint: limit to max 30% body surface area.|
|Wynzora||0.005% + 0.064%||crm||Apply once daily for up to 8wks; max 100g/week. Discontinue when control is achieved.|
|calcitriol||Vectical||3mcg/g||oint||≥2yrs: apply twice daily in AM & PM; max weekly dose (2–6yrs): 100g; (≥7yrs): 200g.|
|halobetasol propionate + tazarotene||Duobrii||0.01% + 0.045%||lotion||Apply once daily; max 50g/week. Discontinue when control is achieved.|
|roflumilast||Zoryve||0.3%||crm||≥12yrs: apply once daily; rub in completely.|
|tapinarof||Vtama||1%||crm||Apply thin layer once daily. Wash hands after application, unless treating the hands.|
|tazarotene||Tazorac||0.05%, 0.1%||gel, crm||Apply once daily in the PM. Gel: limit to max 20% body surface area. Initiate with 0.05% strength; may increase to 0.1% as tolerated and clinically indicated.|
|Interleukin-12 and interleukin-23 antagonist1|
|ustekinumab||Stelara||45mg/0.5mL, 90mg/mL||soln for SC inj||6–17yrs: give SC at Weeks 0 and 4, then every 12wks thereafter. (<60kg): 0.75mg/kg; (60–100kg): 45mg; (>100kg): 90mg. ≥18yrs (≤100kg): initially 45mg SC once, then 4wks later, and then once every 12wks; (>100kg): initially 90mg once, then 4wks later, and then once every 12wks.|
|brodalumab||Siliq||210mg/1.5mL||soln for SC inj||210mg SC at Weeks 0, 1, and 2, then 210mg every 2wks.|
|ixekizumab||Taltz||80mg/mL||soln for SC inj||160mg (given as two 80mg SC injs) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4wks.|
|secukinumab||Cosentyx||75mg/0.5mL, 150mg/mL, 150mg/vial||soln or lyophilized pwd for SC inj||≥6yrs: give SC at Weeks 0, 1, 2, 3, and 4, then every 4wks thereafter. (<50kg): 75mg; (≥50kg): 150mg. ≥18yrs: 300mg (given as two 150mg SC injs) at Weeks 0, 1, 2, 3, and 4, then 300mg every 4wks. For some patients, 150mg dose may be acceptable.|
|guselkumab||Tremfya||100mg/mL||soln for SC inj||100mg SC at Weeks 0 and 4, then every 8wks thereafter.|
|risankizumab-rzaa||Skyrizi||75mg/0.83mL, 150mg/mL||soln for SC inj||150mg at Weeks 0 and 4, then every 12wks thereafter.|
|tildrakizumab-asmn||Ilumya||100mg/mL||soln for SC inj||100mg SC at Weeks 0 and 4, then every 12wks thereafter.|
|Tumor necrosis factor (TNF) blockers1|
|adalimumab||Humira||10mg/0.1mL, 10mg/0.2mL, 20mg/0.2mL, 20mg/0.4mL, 40mg/0.4mL, 40mg/0.8mL, 80mg/0.8mL||soln for SC inj||Initially 80mg SC, followed by 40mg every other week 1wk after initial dose.|
|certolizumab pegol||Cimzia||200mg/mL||soln or pwd for SC inj||400mg (two 200mg inj at separate sites) SC every other week. ≤90kg: may consider 400mg on Day 1, then at Weeks 2 and 4, followed by 200mg every other week.|
|etanercept||Enbrel||25mg/0.5mL, 50mg/mL, 25mg/vial||soln or pwd for SC inj; soln for autoinjector||Give by SC inj. ≥4yrs: (<63kg): 0.8mg/kg (max 50mg) weekly; (≥63kg): 50mg weekly. ≥18yrs: initially 50mg SC twice weekly for 3mos (initial doses of 25mg or 50mg per week were shown to be efficacious). Maintenance: 50mg once weekly.|
|infliximab||Remicade||100mg/vial||lyophilized pwd for IV infusion||5mg/kg IV over ≥2hrs at Weeks 0, 2, 6, then once every 8wks.|
|Tyrosine kinase inhibitor|
|deucravacitinib||Sotyktu||6mg||tabs||6mg once daily|
|acitretin||—||10mg, 17.5mg, 25mg||caps||25–50mg once daily with main meal; may discontinue when lesions resolve. May repeat if relapse occurs.|
|apremilast||Otezla||10mg, 20mg, 30mg||tabs||Starting on Day 1: 10mg in the AM. Day 2: 10mg in AM and 10mg in PM. Day 3: 10mg in AM and 20mg in PM. Day 4: 20mg in AM and 20mg in PM. Day 5: 20mg in AM and 30mg in PM. Following on Day 6 and thereafter: 30mg twice daily (AM & PM).|
|cyclosporine||Gengraf3||25mg, 100mg, 100mg/mL||caps, oral soln||1.25mg/kg twice daily; may increase after 4wks by 0.5mg/kg/day, then adjust at 2-week intervals; max 4mg/kg/day.|
|methotrexate||Otrexup||10mg/0.4mL, 15mg/0.6mL, 17.5mg/0.7mL, 20mg/0.8mL, 22.5mg/0.9mL, 25mg/mL||soln for SC inj||10–25mg once weekly using an oral, IM, SC, or IV form; max 30mg/wk. Use alternative MTX form in patients requiring oral, IM, IV, intra-arterial, or intrathecal dosing, doses <7.5mg/wk or >30mg/wk, high-dose regimens, or dose adjustments <2.5mg increments.|
|Rasuvo||7.5mg/0.15mL, 10mg/0.20mL, 12.5mg/0.25mL, 15mg/0.30mL, 17.5mg/0.35mL, 20mg/0.40mL, 22.5mg/0.45mL, 25mg/0.50mL, 30mg/0.60mL|
|Reditrex||15mg/0.6mL, 20mg/0.8mL, 25mg/mL|
1 These medications should only be used under the guidance and supervision of a physician.
2 Intended to be administered only in conjunction with a schedule of controlled doses of long wave UV radiation. See full labeling for UVA exposure schedule.
3 Not bioequivalent to all other forms of cyclosporine; do not interchange without physician supervision.
Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.